The rationale for the use of GRAs and glucagon agonists in the treatment of patients with type 2 diabetes (55–68% of whom have liver steatosis [73]) and obesity is based on glucagon’s effects on hepatic glucose and lipid metabolism, respectively. The gene discussed is GCG; the disease is type 2 diabetes mellitus.